Related Experiment Videos
[Statins for cardiovascular prevention: is there still a place for cholesterol measurement?]
1Service de Diabétologie, Nutrition et Maladies métaboliques et de Médecine interne générale, Département de Médecine, Université de Liège.
Insights
Statins effectively prevent cardiovascular events, potentially through mechanisms beyond cholesterol reduction. This paper examines optimal statin dosing strategies for primary and secondary prevention.
Area of Science:
- Pharmacology
- Cardiology
- Biochemistry
Context:
- Statins are widely used to lower plasma cholesterol and prevent cardiovascular events.
- Evidence suggests statins' protective effects may extend beyond cholesterol reduction, indicating pleiotropic actions.
- Current understanding necessitates a re-evaluation of statin therapy protocols.
Purpose:
- To discuss the arguments for and against specific cholesterol level targets before and during statin therapy.
- To explore the role of statin pleiotropic effects in cardiovascular event prevention.
- To analyze optimal statin dosing for both primary and secondary cardiovascular prevention.
Summary:
- Statins demonstrate efficacy in cardiovascular event prevention, even at lower initial cholesterol levels.
- The protective benefits may be partly independent of cholesterol reduction, attributed to pleiotropic effects.
- The paper reviews considerations for cholesterol management and statin dosage in diverse patient populations.
Impact:
- Informs clinical decisions regarding statin therapy initiation and monitoring.
- Highlights the importance of considering pleiotropic effects in cardiovascular risk management.
- Contributes to optimizing treatment strategies for patients at risk of cardiovascular events.
Abstract:
Statins, the most popular lipid-lowering agents, have proven their efficacy in preventing cardiovascular events in subjects with lower and lower initial plasma cholesterol levels. Besides, the protective effect does not seem to be directly related neither to the degree of the cholesterol reduction nor to the final level of plasma cholesterol level reached under treatment. Such observations suggest that statins may exert vascular protective effects, at least in part, independently of their specific cholesterol-lowering effect (so-called pleiotropic effects). The present paper will discuss the arguments pro and contra the dosage of cholesterolaemia before initiating a therapy with statin and during treatment follow up, both in subjects with previous cardiovascular events (secondary prevention) and in subjects with a high cardiovascular absolute risk but without previous clinical expression of atherosclerosis (primary prevention).